• We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need optimized assays for investigational toxicology.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon

Next Generation 3D in vitro Modeling of Neurodegenerative and Neuroinflammatory Diseases

On-demand Webinar

Diseases of the nervous system are becoming increasingly prevalent. However, there is a lack of physiologically relevant in vitro models to comprehensively study neurological diseases. Traditionally, researchers have used animal and transwell-based models to study neurodegenerative disorders such as ALS, Multiple Sclerosis (MS), and Alzheimer’s disease. To holistically recapitulate intricate disease pathways and clinical progression, advanced 3D microfluidic systems, such as Organs-on-Chips, have been developed and used to achieve more human-relevant tissue and disease modeling. The Blood-Brain Barrier (BBB) is one of such models. The BBB serves as a physiological and metabolic barrier that plays a key role in maintaining homeostasis in the Central Nervous System (CNS). Doing so ensures a healthy functioning of the CNS. However, this protective function is adapted in neurological diseases, inducing neuroinflammation, which further propels the progression of various neurological diseases.

Immerse yourself in an overview of our 3D in vitro modeling capabilities of neurological diseases and delve deeper into an application of a robust, immune-competent BBB-on-a-chip model used to investigate neuroinflammation.

In this webinar, you will:

  • Discover the models and techniques used to study neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease and ALS
  • Explore how we utilized the OrganoPlate® to develop a human BBB-on-a-chip to model neuroinflammation and transendothelial migration to study neurological diseases
  • Learn about the high-throughput of the OrganoPlate platform and how our OrganoReady® BBB HBMEC can facilitate and aid your research


Watch the webinar here



Xandor Spijkers, PhD is a Scientific Project Lead at MIMETAS. He completed his bachelor’s degree in Neuropsychology at Tilburg University, after which he went on to do a research master's program in Neurosciences at the VU University. His PhD research was a collaborative project between MIMETAS and the University Medical Centre Utrecht and focused on Amyotrophic Lateral Sclerosis (ALS). His current work is oriented towards models of the central and peripheral nervous system.


Arya Lekshmi Nair is a Marie Sklodowska-Curie fellow and Early Stage Researcher affiliated with MIMETAS. She received her bachelor's degree in Biomedical Engineering from SRM University, India and her master's degree in Biomedical Technologies from Eberhard Karls University of Tübingen, Germany. At MIMETAS, she focuses on establishing and developing human blood-brain barrier and neurovascular unit models in the OrganoPlate.




May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all